211 related articles for article (PubMed ID: 33587403)
1. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults.
Faison SL; Fry N; Adewole T; Odebo O; Wang Z; Maletic V; Nasser A
J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):155-162. PubMed ID: 33587403
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults.
Faison SL; Fry N; Adewole T; Odebo O; Schwabe S; Wang Z; Maletic V; Nasser A
Clin Drug Investig; 2021 Feb; 41(2):149-159. PubMed ID: 33368026
[TBL] [Abstract][Full Text] [Related]
3. Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.
Wang Z; Kosheleff AR; Adeojo LW; Odebo O; Adewole T; Qin P; Maletic V; Schwabe S; Nasser A
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1365-1374. PubMed ID: 33943033
[TBL] [Abstract][Full Text] [Related]
4. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
Schein J; Cloutier M; Gauthier-Loiselle M; Catillon M; Xu C; Chan D; Childress A
J Manag Care Spec Pharm; 2024 Jun; 30(6):528-540. PubMed ID: 38824626
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
Roesch B; Corcoran ME; Fetterolf J; Haffey M; Martin P; Preston P; Purkayastha J; Wang P; Ermer J
Drugs R D; 2013 Jun; 13(2):119-28. PubMed ID: 23615868
[TBL] [Abstract][Full Text] [Related]
6. Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree
Wang Z; Kosheleff AR; Adeojo LW; Odebo O; Liranso T; Schwabe S; Nasser A
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):69-79. PubMed ID: 34652564
[TBL] [Abstract][Full Text] [Related]
7. A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects.
Ermer J; Martin P; Corcoran M; Matsuo Y
Neuropsychopharmacol Rep; 2020 Mar; 40(1):16-29. PubMed ID: 31765110
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.
Nasser A; Gomeni R; Wang Z; Kosheleff AR; Xie L; Adeojo LW; Schwabe S
J Clin Pharmacol; 2021 Dec; 61(12):1626-1637. PubMed ID: 34269426
[TBL] [Abstract][Full Text] [Related]
9. Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink.
Ermer J; Corcoran M; Lasseter K; Martin PT
Ther Drug Monit; 2016 Dec; 38(6):769-776. PubMed ID: 27661399
[TBL] [Abstract][Full Text] [Related]
10. An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults.
Ermer J; Haffey MB; Richards C; Lasseter K; Roesch B; Purkayastha J; Corcoran M; Harlin B; Martin P
Clin Drug Investig; 2013 Apr; 33(4):243-54. PubMed ID: 23512639
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Boellner SW; Stark JG; Krishnan S; Zhang Y
Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
[TBL] [Abstract][Full Text] [Related]
12. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Findling RL; Wu J; Kollins SH; Wang Y; Martin P; Robertson B
J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):128-136. PubMed ID: 32233956
[No Abstract] [Full Text] [Related]
13. Impact of Viloxazine Extended-Release Capsules (Qelbree
Wang Z; Liranso T; Maldonado-Cruz Z; Kosheleff AR; Nasser A
Clin Drug Investig; 2024 May; 44(5):303-317. PubMed ID: 38598106
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
Adler LA; Alperin S; Leon T; Faraone SV
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic and exposure-response analyses of d-amphetamine after administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD patients.
Tsuda Y; Matsuo Y; Matsumoto S; Wajima T
Drug Metab Pharmacokinet; 2020 Dec; 35(6):548-554. PubMed ID: 33082099
[TBL] [Abstract][Full Text] [Related]
16. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
[TBL] [Abstract][Full Text] [Related]
17. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
Frampton JE
Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
[TBL] [Abstract][Full Text] [Related]
18. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.
Krishnan SM; Pennick M; Stark JG
Clin Drug Investig; 2008; 28(12):745-55. PubMed ID: 18991468
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
Sikes C; Stark JG; McMahen R; Engelking D
Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
[TBL] [Abstract][Full Text] [Related]
20. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
